iBio Announces Preclinical Data In Which An Engineered Amylin Receptor Agonist Antibody Reduced Acute Food Intake In A Mouse Model Of Obesity By 60%, Equivalent To The Reduction In Food Intake From A Clinically Advanced Dual Amylin And Calcitonin Receptor Agonist Peptide (67%).
Benzinga Newsdesk 1 year ago
BiotechNewsHealth CareGeneral
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonistFindings support the potential of
- Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
- Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases